Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 6/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379161 | 0.89 | CDC25B (0.35) | HPGDPOLBPKMGSK3BALOX12 | |
| SCHEMBL496945 | 0.85 | MAPT (0.34) | HPGDPOLBPKMGSK3BALOX12 | |
| SCHEMBL497129 | 0.85 | KMT2A (0.41) | HPGDPOLBPKMGSK3BALOX12 | |
| SCHEMBL1249099 | 0.84 | HPGD (0.40) | HPGDPOLBPTPN1PIM1ALDH1A1 | |
| SCHEMBL2788176 | 0.84 | DYRK3 (0.35) | HPGDPOLBPKMGSK3BALOX12 | |
| SCHEMBL2788331 | 0.83 | MEN1 (0.44) | HPGDPOLBGSK3BCDC25BHSD11B1 | |
| SCHEMBL497531 | 0.82 | NAT1 (0.39) | HPGDPOLBGSK3BPIM1ALDH1A1 | |
| SCHEMBL497021 | 0.82 | HPGD (0.32) | HPGDPOLBGSK3BALDH1A1LMNA | |
| SCHEMBL497261 | 0.81 | KMT2A (0.48) | HPGDPOLBPKMALOX12CRHBP | |
| SCHEMBL496965 | 0.81 | MEN1 (0.32) | HPGDPOLBPKMCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | claimed |
| JP-2007500171-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1648452-A1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-04-26 | — | — | EP | claimed |
| WO-2005011686-A1 | 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | claimed |
| US-8106214-B2 | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors | MERCK SERONO SA (CH) | 2012-01-31 | — | — | US | disclosed |
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1931424-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030360-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | disclosed |
| EP-1648452-A1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005011686-A1 | 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | HPGD 1757/4885POLB 1667/4885PKM 490/4885 |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | PI4K2B, PI4KA, PTK2B | HPGD 1525/4885POLB 2638/4885PKM 752/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | HPGD 3709/4885POLB 3358/4885PKM 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.